01780nam a2200277   4500001000800000005001700008007000300025008004100028040000800069041000800077100003100085245008800116300002500204520085500229650004301084650004701127650002101174650002001195650004201215700002901257700003101286700002701317773011001344942003101454999001701485ESSALUD20260903092258.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aMaini, Luca eAutor954502  aMedicaid’s GENEROUS Most-Favored-Nation Pricing Model — Promise and Limitations  apáginas: 1772-1774  aOn November 10, 2025, the Centers for Medicare and Medicaid Services (CMS) released a request for applications seeking pharmaceutical manufacturer participation in the GENEROUS (Generating Cost Reductions for U.S. Medicaid) model — a pilot program intended to reduce Medicaid drug spending and improve drug access. Under the program, participating manufacturers will offer supplemental rebates tied to prices in non-U.S. Group of Seven (G7) countries (Canada, France, Germany, Italy, Japan, and the United Kingdom) plus Denmark and Switzerland in exchange for federally negotiated coverage criteria. State Medicaid programs will then decide whether to accept those coverage terms. Participating states will forgo any additional state-specific rebates they previously negotiated but will retain Medicaid Drug Rebate Program (MDRP) statutory rebates.  aCOSTO DE LA ATENCIÓN MÉDICA954150  aMEDICAMENTOS, DISPOSITIVOS Y LA FDA954223  aMEDICARE 954503  aMEDICAID954504  aIMPLEMENTACIÓN DE LA REFORMA954441  aSachs, Rachel E. 954505  aKyle, Michael Anne 954506  aKakani, Pragya 9545070 022717922676dMassachusetts NEJM GroupoNEJM015tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-31zsqb  c22913d22913